Malaria prophylaxis in patients with renal impairment: A review

Drug Safety

Volumn 36, Issue 2, 2013, Pages 83-91

  Amet, Sabine ^a   Zimner Rapuch, Sarah ^a   Launay Vacher, Vincent ^a   Janus, Nicolas ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLOROQUINE PLUS PROGUANIL; DOXYCYCLINE; DRUG METABOLITE; MEFLOQUINE; PROGUANIL;

ABDOMINAL CRAMP; ACUTE KIDNEY FAILURE; ANTIMALARIAL ACTIVITY; ARTICLE; BLOOD TOXICITY; CACHEXIA; CARDIOVASCULAR DISEASE; CREATININE CLEARANCE; CYANOSIS; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; DRUG TREATMENT FAILURE; GASTROINTESTINAL DISEASE; GOLD STANDARD; HEADACHE; HEART ARREST; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFECTION RISK; INTOXICATION; ISOTOPE LABELING; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; LEUKOPENIA; MALARIA; MALARIA CONTROL; MEGALOBLASTIC ANEMIA; METHEMOGLOBINEMIA; OUTCOME ASSESSMENT; PANCYTOPENIA; PARASITE PREVALENCE; PLASMA CLEARANCE; PLASMA PROTEIN BINDING; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM VIVAX; PRIORITY JOURNAL; RESPIRATORY ARREST; RISK ASSESSMENT; SEIZURE; SHOCK; SKIN DISEASE; TRAVEL; TREATMENT DURATION; URINARY EXCRETION; VISUAL DISORDER; VOMITING; WORLD HEALTH ORGANIZATION;

ANTIMALARIALS; DRUG DOSAGE CALCULATIONS; DRUG THERAPY, COMBINATION; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; RENAL INSUFFICIENCY; TRAVEL;

EID: 84876573108     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0017-y     Document Type: Article

References (56)

1. Garcia LS. Malaria. Clin Lab Med. 2010;30(1):93-129.
2. Kihara M, Carter JA, Newton CR. The effect of Plasmodium falciparum on cognition: a systematic review. Trop Med Int Health. 2006;11(4):386-97.
3. WHO. World malaria report 2011. http://www.who.int/malaria/world-malaria- report-2011/burdenestimatesbriefing2011.pdf. Accessed 12 Jun 2012.
4. Rossi I, Dacremont V, Peytremann-Bridevaux I. Prevention of malaria in travellers: which antimalarial is best? Rev Med Suisse. 2010;6:1840.
5. Field V, Gautret P, Schlagenhauf P, et al. Travel and migration associated infectious diseases morbidity in Europe, 2008. BMC Infect Dis. 2010;10:330.
6. WHO. Malaria. In: International travel and health 2010. Geneva: WHO, 2010. http://www.who.int/ith/ITH2010chapter7.pdf. Accessed 27 Dec 2012.
7. Fernando SD, Rodrigo C, Rajapakse S. The 'hidden' burden of malaria: cognitive impairment following infection. Malar J. 2010;9:366.
8. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038-47.
9. Launay-Vacher V, Spano JP, Janus N, et al. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol. 2009;70:124-33.
10. Karie S, Launay-Vacher V, Deray G. GPR: antibiotiques et antifongiques. 3rd edition. Guide de prescription des médicaments chez le patient insuffisant rénal. Paris: Meditions International; 2008.
11. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038-47.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
13. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-70.
14. Froissart M, Rossert J, Jacquot C, et al. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005;16:763-73.
15. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-266.
16. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089-100.
17. Stevens LA, Levey AS. Use of the MDRD study equation to estimate kidney function for drug dosing. Clin Pharmacol Ther. 2009;86(5):465-7.
18. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757-77.
19. Launay-Vacher V, Storme T, Izzedine H, et al. Pharmacokinetic changes in renal failure. Presse Med. 2001;30(12):597-604.
20. Thorogood N, Atwal S, Mills W, et al. The risk of antimalarials in patients with renal failure. Postgrad Med J. 2007;83(986):e8.
21. ® [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0130632.htm. Accessed 8 Aug 2012.
22. Stahel E, Druilhe P, Gentilini M. Antagonism of chloroquine with other antimalarials. Trans R Soc Trop Med Hyg. 1988;82(2):221.
23. White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet. 1985;10:187-215.
24. Salako LA, Walker O, Iyun AO. Pharmacokinetics of chloroquine in renal insufficiency. Afr J Med Med Sci. 1984;13(3-4):177-82.
25. Akintonwa A, Odutola TA, Edeki T, et al. Hemodialysis clearance of chloroquine in uremic patients. Ther Drug Monit. 1986;8(3):285-7.
26. Launay-Vacher V, Izzedine H, Baumelou A, et al. FHD: an index to evaluate drug elimination by hemodialysis. Am J Nephrol. 2005;25:342-51.
27. Chiluba EM, Fletcher KA, Price AH. The pharmacokinetics of proguanil in human subjects following a single oral dose. Afr J Med Med Sci. 1987;16(1):43-6.
28. Tattersall JE, Greenwood RN, Baker LR, et al. Proguanil poisoning in a hemodialysis patient. Clin Nephrol. 1987;28(2):104.
29. Boots M, Phillips M, Curtis JR. Megaloblastic anemia and pancytopenia due to proguanil in patients with chronic renal failure. Clin Nephrol. 1982;18(2):106-8.
30. Sirsat RA, Dasgupta A. Haematological complications of proguanil in a patient with chronic renal failure. Nephron. 1997;75(1):108.
31. ® [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0207917.htm. Accessed 8 Aug 2012.
32. ® [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0167697.htm. Accessed 8 Aug 2012.
33. ® [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0173830.htm. Accessed 8 Aug 2012.
34. Rolan PE, Mercer AJ, Tate E, et al. Disposition of atovaquone in humans. Antimicrob Agents Chemother. 1997;41(6):1319-21.
35. Spencer CM, Goa KL. Atovaquone: a review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs. 1995;50(1):176-96.
36. Hughes WT, Kennedy W, Shenep JL, et al. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. J Infect Dis. 1991;163(4):843-8.
37. Aronoff GR, Bennett WM, Berns JS, et al. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. Philadelphia: American College of Physicians; 2007.
38. Jolink H, den Hartigh J, Visser LG, et al. Pancytopenia due to proguanil toxicity in a returning traveller with fever. Eur J Clin Pharmacol. 2010;66(8):811-2.
39. ® [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0201777.htm. Accessed 8 Aug 2012.
40. Development of mefloquine as an antimalarial drug. Bull World Health Organ. 1983;61(2):169-178.
41. Launay-Vacher V, Bassilios N, Deray G. GPR: antifongiques et antiparasitaires. Guide de prescription des médicaments chez le patient insuffisant rénal. Paris: Méditions International; 2002.
42. Crevoisier CA, Joseph I, Fischer M, et al. Influence of hemodialysis on plasma concentration-time profiles of mefloquine in two patients with end-stage renal disease: a prophylactic monitoring study. Antimicrob Agents Chemother. 1995;39(8):1892-5.
43. Desjardins RE, Canfield CJ, Haynes JD, et al. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979;16(6):710-8.
44. Palmer KJ, Holliday SM, Brogden RN. Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1993;45(3):430-75.
45. ® [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0173656.htm. Accessed 8 Aug 2012.
46. Bassilios N, Launay-Vacher V, Deray G. GPR: antibactériens. Guide de prescription des médicaments chez le patient insuffisant rénal. Paris: Méditions International; 2002.
47. Fabre J, Milek EF, Kalfopoulos P, et al. Tetracycline kinetics in man: digestive absorption and serum concentration. Schweiz Med Wochenschr. 1971;101(17):593-8.
48. Whelton A, Schach von Wittenau M, Twomey TM. Doxycycline pharmacokinetics in the absence of renal function. Kidney Int. 1974;5(5):365-71.
49. Ao NK, Taneja OP, Bhatia VN, et al. Serum concentration and urinary excretion of doxycycline in normal subjects and patients with renal insufficiency. Chemotherapy. 1974;20(3):129-40.
50. Lee P, Crutch ER, Morrison RB. Doxycycline: studies in normal subjects and patients with renal failure. N Z Med J. 1972;75:355-8.
51. Barza M, Schiefe RT. Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part I: tetracyclines. Am J Hosp Pharm. 1977;34(1):49-57.
52. Houin G, Brunner F, Nebout T, et al. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br J Clin Pharmacol. 1983;16(3):245-52.
53. Jaffe JM, Colaizzi JL, Poust RI, et al. Effect of altered urinary pH on tetracycline and doxycycline excretion in humans. J Pharmacokinet Biopharm. 1973;1(4):267-82.
54. Shmuklarsky MJ, Boudreau EF, Pang LW, et al. Failure of doxycycline as a causal prophylactic agents against Plasmodium falciparum malaria in healthy non immune volunteers. Ann Intern Med. 1994;120(4):294-9.
55. Institut de veille Sanitaire. Health recommendations for travellers, 2012. Bulletin épidémiologique hebdomadaire no 20-21, 2012. http://www.invs.sante.fr/Publications-et-outils/BEH-Bulletin-epidemiologique- hebdomadaire/Derniers-numeros-et-archives/Archives/2012/BEH-n-20-21-20122. Accessed 27 Dec 2012.
56. Centers for Disease Control and Prevention. Malaria information and prophylaxis, by country. http://www.cdc.gov/malaria/travelers/country-table/t. html. Accessed 14 Jan 2013.